联合分析XRCC1、XPD和GSTP1基因单核苷酸多态性在铂类药物化疗敏感性中的预测作用

目的 联合分析X线修复交叉互补基因1（X-rayCOrSS—complementing1，XRCCl）第194和399位点，着色性干皮病基因D（XerodermapigmentosumgroupD，XPD）第312位点及谷胱甘肽-s-转移酶P1基因（GlutathioneS-Transferasepl，GSTPl）第105位点的单核苷酸多态性（singlenucleotidepolymorphisms，SNPs）在预测铂类药物化疗敏感性中的作用。方法采用基因测序法对50例恶性肿瘤患者的外周血进行XRCCl、XPD和GSTPl基因单核苷酸多态性（SNPs）检测，分析各基因型与铂类药物化疗敏感性的关系。结果有效率高的基因型为：XRCC1194位点的Arg／Trp和Trp／Trp，XRCC1399位点的Arg／Arg，XPD312位点的Asn／Asn，GSTPl105位点的Val／Val，它们的化疗有效率分别为57．1％、75．0％、60．9％、85．7％、87．5％。有两个以上和有1个或0个高效基因型患者的化疗有效率分别是78．9％、36．4％和0，有两个以上高效基因型的患者的敏感性明显高于有1个或0个高效基因型的患者，其差异有统计学意义（x2=25．79，P〈0．01）。结论对XRCC1、XPD和GSTP1基因的单核苷酸多态性进行联合检测，可能预测患者对铂类药物的敏感性。

Predictive effect of combined evaluation of XRCC1, XPD and GSTP1 single nucleotide polymorphisms in platinum based chemotherapy

Objective To investigate the predictive value of combined analysis on single nucleotide polymorphisms (SNPs) of X-ray cross-complementing1 ( XRCC1 ) gene 194 and 399 codon,xeroderma pigmentosum group D (XPD) gene 312 codon and glutathione S-transferase P1 (GSTP1) gene 105 codon in platinum based chemotherapy.Methods Direct sequencing was performed to detect XRCC1,XPD and GSTP1 genotypes in peripheral blood from 50 cancer patients receiving platinum-based chemotherapy.Genetic polymorphisms of these genes related to sensitivity of platinum were reviewed.Results Favorable genotypes were Arg/Trp and Trp/Trp in XRCC1 194 codon,Arg/Arg in XRCC1 399 codon,Asn/Asn in XPD 312 codon and Val/Val in GSTP1 105 codon.The response rate to chemotherapy was 57.1％,75.0％,60.9％,85.7％ and 87.5％,respectively.The response rate for patients possessing ≥2 favorable genotypes and those possessing 1 or 0 favorable genotype was 78.9％,36.4％ and 0,respectively.Patients possessing ≥2 favorable genotypes demonstrated higher sensitivity to platinum based chemotherapy,compared with those possessing 1 or 0 favorable genotype ( x2 =25.79,P ＜ 0.01 ).Conclusions Combination analysis of genomic polymorphisms of XRCC1,XPD and GSTP1 may be useful in predicting sensitivity of platinum based chemotherapy.